Overview

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors (Closed to Accrual 12/11/2008)

Status:
Completed

Trial end date:
2011-03-29

Target enrollment:

Participant gender:

Summary

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with gemcitabine and capecitabine may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of gemcitabine and capecitabine when given together with imatinib mesylate in treating patients with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

University of Nebraska

Collaborator:

National Cancer Institute (NCI)

Treatments:

Capecitabine
Gemcitabine
Imatinib Mesylate